sitagliptin-phosphate and Anemia

Randomized clinical trials have not shown an additional clinical benefit of sitagliptin treatment over conventional treatment alone. However, studies of sitagliptin treatment have not examined the relationship between anemia and treatment group outcomes.. The PROLOGUE study is a prospective clinical trial of 442 participants with type 2 diabetes mellitus (T2DM) randomized to sitagliptin treatment or conventional treatment which showed no treatment differences [Estimated mean (± standard error) common carotid intima-media thickness (CIMT) was 0.827 ± 0.007 mm and 0.837 ± 0.007 mm, respectively, with a mean difference of -0.009 mm (97.2% CI -0.028 to 0.011,. The treatment group difference in baseline-adjusted mean common carotid artery- (CCA-) IMT at 24 months was -0.003 mm (95% CI -0.022 to 0.015,. These data suggest that nonanemia may indicate a potentially large subgroup of those with T2DM patients that sitagliptin therapy has a better antiatherosclerotic effect than conventional therapy. Further research is needed to confirm these preliminary observations.

Topics: Aged; Anemia; Atherosclerosis; Carotid Artery, Common; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Male; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome